Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio

Published 31/07/2025, 12:20
© Reuters

Investing.com -- Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across its Growth Portfolio, prompting the pharmaceutical giant to raise its full-year guidance. The stock rose 2.2% following the announcement.

The company reported adjusted earnings of $1.46 per share for the second quarter, significantly beating the analyst estimate of $1.06. Revenue came in at $12.27 billion, surpassing the consensus estimate of $11.34 billion and representing a 1% increase YoY. The results include a $0.57 per share impact from an acquired in-process research and development charge associated with the BioNTech (NASDAQ:BNTX) strategic partnership.

Bristol-Myers Squibb (NYSE:BMY)’s Growth Portfolio, which includes products like Opdivo, Reblozyl, and Breyanzi, generated $6.6 billion in revenue, an 18% increase YoY (17% excluding foreign exchange impact). This growth helped offset a 14% decline in the Legacy Portfolio, which was affected by generic competition and U.S. Medicare Part D redesign.

"We are making good progress rewiring the company for long-term growth. In the second quarter, we delivered strong results across our Growth Portfolio, continued to optimize our cost structure, and added to our innovative pipeline with strategic partnerships," said Christopher Boerner, board chair and chief executive officer.

Based on the strong quarterly performance, Bristol-Myers Squibb raised its full-year 2025 revenue guidance to approximately $46.5 billion to $47.5 billion, up from the previous range of $45.8 billion to $46.8 billion. The company also lowered its adjusted earnings forecast to $6.35 to $6.65 per share from $6.70 to $7.00. It now includes the unfavorable $0.57 per share impact from the BioNTech charge.

Among the standout performers in the Growth Portfolio, Breyanzi saw a 125% YoY increase in sales to $344 million, while Camzyos grew 87% to $260 million. The company’s flagship cancer drug Opdivo generated $2.56 billion in revenue, a 7% increase YoY.

U.S. revenues decreased 3% to $8.5 billion, while international revenues increased 10% to $3.8 billion (8% excluding foreign exchange impact).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.